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Purpose: To evaluate the efficacy and tolerability of Xiloial® monodose eyedrops in the 
treatment of patients suffering from subjective symptoms of discomfort related to disposable 
soft contact lens (dSCL) wear.
Methods: Fifteen (12 female, three male, medium age 39 ± 9 years) dSCL wearers were 
enrolled. Inclusion criteria were Ocular Surface Disease Index (ODSI) symptom questionnaire 
score .12, tear film break-up time (TFBUT) ,10 sec, Schirmer test I .10 mm over five minutes, 
mild punctuate keratopathy, and conjunctival staining (Oxford grading #4). Monodose Xiloial 
eyedrops were administered three times daily for a two-month period. Patients were evaluated at 
enrollment, after three days of washout (baseline), and after one and two months of treatment, 
by OSDI score, Schirmer test I, TFBUT, ferning test, ocular surface damage (Oxford grade), 
and serum albumin in tears (index of passive exudation related to serum leakage).
Results: At endpoint versus baseline, respectively, the mean ± standard deviation of all variables 
improved as follows: OSDI (8.5 ± 3 versus 20.2 ± 1.6); TFBUT (9.6 ± 1.1 versus 7.1 ± 1.0); 
Oxford grading (0.5 ± 0.1 versus 3.6 ± 0.8); ferning test (2 ± 1 versus 2.4 ± 0.5); and Schirmer 
test I (14.6 ± 1.1 versus 12 ± 2.1), with P , 0.05 for all variables (Friedman and Wilcoxon 
tests). Tolerability was high, with no adverse events noted.
Conclusions: A two-month treatment with Xiloial showed good tolerance and appeared to 
reduce ocular surface damage and symptoms of discomfort.
Keywords: discomfort, dry eye, disposable contact lens, biopolymer tamarind seed 
polysaccharide–hyaluronic acid
Introduction
Symptoms of ocular surface discomfort are common in contact lens wearers, affecting 
about half of them.1,2 As many as 20% of contact lens wearers experience symptoms that 
are severe enough to reduce their wearing time.3,4 Furthermore, 12%–24% of contact 
lens patients discontinue contact lens wear permanently.4,5 The most common reason 
for lens discontinuation is discomfort, affecting about 49%–72% of wearers.5–7 Other 
symptoms frequently affecting lens wearers are dryness, itchiness, grittiness, photopho-
bia, soreness, and pain.4 In spite of this, 65% of contact lens wearers think that this is the 
ideal form of visual correction.4 The speculated mechanism of contact lens-related dis-
comfort and dryness is multifactorial, including evaporation,8 hypoesthesia,9 decreased 
tear production with concurrent increased osmolarity,10 and inflammation.11–13
Tear film is critical to successful wearing of contact lenses. A stable tear film is impor-
tant to promote clear vision and to reduce optical aberration created by tear film breakup.14 Clinical Ophthalmology  2010:4 submit your manuscript | www.dovepress.com
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Instillation of tear substitutes may improve the optical quality 
of vision in contact lens-related dry eye syndrome,15,16 and 
preservative-free tear substitute formulations are preferable 
because of the toxicity of preservatives.17
Evolving concepts in tear substitute formulation suggest 
that better compliance can be achieved by improving the 
stability of the tear film/corneal epithelium interface with 
mucoadhesive properties and enhanced retention time on 
the surface.17 In addition, a hypotonic substitute can lower 
tear hyperosmolarity, a common feature in any type of dry 
eye-related disease.18
The present study evaluated the efficacy and tolerability 
of a two-month treatment in symptomatic disposable soft 
contact lens wearers with an innovative preservative-free 
hypo-osmolar copolymer already commercially available in 
Italy (Xiloial® eyedrops; Farmigea, Pisa, Italy), formulated 
to strengthen the synergistic properties of hyaluronic acid 
and tamarind seed polysaccharide (TSP).
Methods
study population
Fifteen disposable contact lens wearers (12 women aged 
40 ± 9 years, three men aged 37 ± 9 years) were enrolled at 
one research site in Bologna, Italy. Patients were full-time 
contact lens wearers, and brand and material of contact lens 
type, replacement schedule, and solutions used are reported in 
Table 1. The study was approved by the Independent Ethics 
Committee and conducted in accordance with the ethical 
principles of the Declaration of Helsinki and the current 
legislation on clinical research in Italy. All subjects signed 
an informed consent form before starting the study.
Materials
Sterile saline (0.9% NaCl; Mini-Plasco, B. Braun,   Meisungen, 
Germany) was used for the washout period. Monodose Xiloial 
eyedrops (hyaluronic acid 0.2% and 0.2% TSP, 280 mosm/L, 
pH 7.4) was used as the test solution.
study design
This was a prospective, open-label, single-center study to 
investigate the effect of Xiloial treatment on discomfort in 
disposable contact lens wearers without suspending lens 
wear during the treatment period. The study included four 
visits during two months, ie, visit 0 (V0, screening), visit 
1 (V1, day 0/baseline, made 1–3 days after V0), visit 2 
(V2, made 30 days after V1), visit 3 (V3, endpoint, 60 days 
after V1) .
inclusion and exclusion criteria
Patients older than 18 years, with a score .12 on the Ocular 
  Surface Disease Index (OSDI) symptom questionnaire,19 
tear film break-up time (TFBUT) lower than 10 seconds, 
and Schirmer test I .10 mm in five minutes were enrolled. 
Patients with punctuate keratopathy .1 by Oxford   grading20 
were excluded, as well as pregnant women, and people with 
concurrent ocular surface pathologies, eye surgery in the last 
six months, concomitant ocular treatment, (except for tear 
substitutes), or known to be allergic to any of the components 
of Xiloial (Table 2).
Table 1 Contact lens types (brand and material), replacement schedule, solutions, wear length (years and daily) are listed for each 
enrolled patient
Patient Wear/day  
(hours)
Wear/total  
(years)
Material Replacement  
schedule
Contact lens 
solution
Past 
intolerance
1 10 5 Iotrafilcon A 1 day none yes
2 10 8 Etafilcon A 15 days Opti-Free  no
3 10 5 Etafilcon A 1 day none yes 
4 10 5 Omafilcon A 1 day none yes
5 10 5 Etafilcon A 1 day none yes
6 8 1 Hilafilcon B 1 day none no
7 10 5 Nelfilcon A 1 day none yes
8 10 8 Polymacon 15 days renu MultiPlus  no
9 10 8 Galifilcon A 7 days  AOsept  no
10 12 10 Iotrafilcon A 1 day none yes
11 12 12 Hilafilcon B 1 day none yes
12 12 10 Etafilcon A 15 days Opti-Free  no
13 8 5 Polymacon 15 days renu MultiPlus  no
14 8 12 Etafilcon A 15 days AOsept  no
15 12 12 Polymacon 15 days renu MultiPlus  no
Mean ± sD 10.1 ± 1.4 7.6 ± 2.8
Abbreviation: sD, standard deviation.Clinical Ophthalmology  2010:4 submit your manuscript | www.dovepress.com
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Procedure
At the screening visit, subjects’ demographic information 
was recorded, along with current/prior use of medications, 
tear substitutes, and ocular pathologies. Subjects who met 
the inclusion criteria signed the informed consent and were 
enrolled. They were then given saline solution as a washout to 
minimize any effect from previous medication use. Subjects 
were instructed to use the saline drops three times daily in 
both eyes, and to refrain from administering any other tear 
drops after 8.00 am on the day of their next visit.
After 1–3 days, subjects returned (V1) for eligibility 
follow-up examination, at which the TFBUT, Schirmer 
test I, and OSDI questionnaire were repeated. In addition, 
the ferning test and measurement of exudated serum albumin 
in tears were carried out. Subjects who remained eligible for 
the study were dispensed Xiloial monodose eyedrops and 
were instructed to use one drop in each eye (upon awakening 
without contact lenses in, early afternoon with contact lenses 
in, and before bedtime without contact lenses in).
After 30 (± 2) days (V2), subjects returned for follow-up. 
The same examination measurements and questions were 
repeated as for V0, except for the ferning test and serum 
albumin measurement. Tolerability was assessed by visual 
analog scale scoring of specific symptoms (blurring, redness, 
itching, stinging after instillation) and any adverse events 
were recorded.
The same examination as for V0 was then repeated after 
a further 30 (± 2) days (V3), which represented the endpoint 
of the study.
Office visits were performed after contact lens removal, 
and the conditions were the same for all visits in that they 
were done at approximately the same time of day (in the early 
afternoon), and in a dim-lit room controlled for temperature 
and humidity. A slit-lamp biomicroscope examination 
was conducted at all visits by two independent examiners 
(VP and NB) to record any abnormalities in the conjunctiva, 
lids/eyelashes, anterior chamber, iris, and lens.
TFBUT was measured and recorded (average of three 
measurements) using 5 µL sodium fluorescein (Fluoralfa 
0.25%; Alfa Intes, Casoria, Italy). Schirmer test I was 
performed by using validated sterile test strips (ContaCare 
Ophthalmics and Diagnostics, Gujarat, India), as described 
elsewhere.21 To quantify corneal and conjunctival surface 
damage, fluorescein sodium staining was graded against stan-
dard charts according to the Oxford grading system,20 with 
the aid of a yellow Kodak Wratten 12 barrier filter. The fern-
ing test was performed as previously described22 at baseline 
and at endpoint. The patterns of arborisation (ferning) from 
a drop of tear collected from the lower meniscus and allowed 
to dry by evaporation were   classified as Types I–IV (Type I, 
uniform arborisation; Type II, empty spaces begin to appear 
among ferns; Type III, single ferns are small, incomplete 
with rare or no branching; Type IV , no ferns), where Types 
I and II are reported to be normal, and Types III and IV are 
reported to be abnormal.22
Exudated serum albumin was measured at baseline and 
endpoint in tear samples using a commercial enzyme-linked 
immunosorbent assay kit (Bio-Rad, Hercules, CA) according 
to the manufacturer’s instructions, and 10 µL unstimulated 
tears were collected from each subject using a laboratory 
micropipette (Pipetman®; Gilson Intl BV , The Hague, The 
Netherlands) with a sterile disposable tip.
statistical analysis
We collected data for the more uncomfortable eye, or 
arbitrarily from the right eye in case of equivalence. Data were 
statistically analyzed using SPSS 9.0 (SPSS Inc., Chicago, IL) 
and MedCalc 5.0 (MedCalc Software, Mariakerke, Belgium) 
software. The Wilcoxon matched-pairs test was applied for 
ferning and albumin data, while the nonparametric paired 
Friedman test was used to evaluate all other variables. 
Values for P # 0.05 were regarded as statistically signifi-
cant. Descriptive statistics were performed for all variables, 
ie, mean and standard deviation (SD). Spearman’s correlation 
analysis was applied to verify the relationship between 
variables and data from the worn contact lens regimen, its 
duration, and any history of intolerance.
Results
All subjects successfully completed the study. Data are sum-
marized in Table 3 and graphed in Figure 1a–f. No significant 
changes in any of the tests applied were observed between 
screening and baseline visits.
symptoms of ocular discomfort
A progressive and significant lowering of discomfort symptoms 
was found after one month of treatment. At the endpoint, OSDI 
score was reduced to more than half that recorded at baseline 
(Table 3, Figure 1a). All patients homogeneously displayed the 
same trend, and no correlation was found between the time of 
symptom recovery and any contact lens wear parameter.
Tear film break-up time
A significant increase in TFBUT was found after one 
month of treatment, which increased even further at the 
endpoint visit, matching the results versus baseline (Table 3, Clinical Ophthalmology  2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1038
Versura et al
Figure 1b). A progressive increase in TFBUT values was 
recorded in all patients in both eyes.
Ocular surface damage
Ocular surface epithelial damage (by Oxford grading score) 
was significantly reduced in six of 15 patients after one 
month of treatment. The damage score disappeared at the 
endpoint of two months’ treatment in eight of 15 patients, 
despite ongoing contact lens wear (Table 3, Figure 1c). Very 
mild conjunctival staining residues (score 1 or 2) were found 
in the remaining seven patients at the endpoint. The timing 
of recovery from damage did not appear to be related to any 
contact lens wear parameters.
Ferning test
Ferning grade was reduced in eight subjects and unchanged 
in seven subjects after two months of treatment. Statistical 
analysis demonstrated a significant (P = 0.03) reduction of 
values at endpoint versus baseline (Table 3, Figure 1d).
schirmer value
Four patients did not show any change in the Schirmer 
value, while a mild increase was observed in the remaining 
11 patients. The Schirmer value significantly increased at the 
endpoint and was evident only after two months of treatment 
(Table 3, Figure 1e).
Albumin in tears
Inhomogeneous results were obtained for exudated serum 
albumin in tears. Analyzing the data as a whole, no statisti-
cally significant difference was demonstrated at the endpoint 
versus baseline (Table 3, Figure 1f). Only the subgroup of 
patients who had not experienced any contact lens wear intol-
erance in the past showed a statistically significant decrease 
in exudated serum albumin at the endpoint versus baseline 
(0.359 ± 0.04 versus 0.388 ± 0.03, P = 0.007, Wilcoxon test) 
but no correlation was found with other contact lens wear 
characteristics.
Tolerability
The visual analog scale tolerability questionnaire showed a very 
good response to treatment. No blurred vision, ocular redness, 
burning, or itching were reported, nor any adverse events.
Discussion
Xiloial is a new ophthalmic preparation based upon the 
unique synergistic action of TSP and high molecular weight 
hyaluronic acid obtained by biotechnologic synthesis.
TSP is a neutral polymer showing a branched-chain 
structure similar to that of corneal and conjunctival mucus 
transmembrane proteins, specifically MUC1. This par-
ticular structure accounts for distinctive mucomimetic, 
mucoadhesive, and pseudoplastic properties23,24 which render 
Table 3 summary of study results
Parameter* Screening visit Baseline 30 days 60 days Level of significance  
P , 0.05
OsDi 20.20 ± 1.66 20.20 ± 1.78 14.40 ± 2.97 8.5 ± 3.00 P , 0.05 (Friedman test)
TFBUT 7.07 ± 1.03 7.07 ± 0.80 8.20 ± 0.77 9.60 ± 1.12 P , 0.05 (Friedman test)
Oxford grading 3.67 ± 0.82 3.67 ± 0.82 2.07 ± 0.96 0.53 ± 0.64 P , 0.05 (Friedman test)
Ferning test - 2.4 ± 0.47 - 2.03 ± 0.13 P , 0.05 (Wilcoxon test)
schirmer test i 12 ± 2.10 13 ± 2.36 13.93 ± 1.91 14.60 ± 1.06 P , 0.05 (Friedman test)
exudated serum albumin - 0.354 ± 0.06 - 0.356 ± 0.03 ns (Wilcoxon test)
Note: *Mean ± standard deviation. 
Abbreviations: OSDI, Ocular Surface Disease Index; TFBUT, tear film break-up time; NS, not significant.
Table 2 Methods and tests utilized in the study, listed in sequence of performance
Test sequence Basis Values to be recorded Pathologic values
1. OsDi questionnaire subjective symptoms score 1–100 .1219
2. schirmer test i indirect measure of total tear  
secretion
mm wetting in five  
minutes
#5 mm/5 min21
3. Ferning test An index of tear stability grade i/iV $grade ii/iii22
4.   Tear collection for albumin dosage An index of blood barrier breakdown 
and passive exudation
mg/mL $0.130 mg/mL31
5. TFBUT An index of tear film stability seconds #10 sec21
6. Oxford grading An index of ocular surface damage grade 0–3 for six areas $9/1820
Abbreviations: OSDI, Ocular Surface Disease Index; TFBUT, tear film break-up time.Clinical Ophthalmology  2010:4 submit your manuscript | www.dovepress.com
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TSP suitable for management of signs and symptoms of dry 
eye. Hyaluronic acid (also termed sodium hyaluronate) is a 
non-Newtonian polymer which shows a good retention time 
on the ocular surface, has viscosity already at low concen-
tration, thus reducing rubbing stresses during blinking and 
stabilizing tear film, thereby delaying tear evaporation.25
The action of these two agents in separate formulations 
has been investigated in the past26,27 in dry eye related to 
contact lens wear. To our knowledge, the present research is 
the first to analyze the synergistic effect of a new formulation 
containing both agents used in contact lens wearers.
Contact lens wearers having a replacement regimen less 
than one month were selected for this study because this 
time schedule is becoming popular in many countries.28 As 
already reported, discontinuation of contact lens wear is 
strictly related to onset of symptoms of discomfort, which 
reduce daily wear at first, and then progresses to abandon-
ment of contact lens wear if management and therapy are 
unsuccessful.4
Patients included in our study had worn contact lenses 
continuously for five years or more, and about than half of 
them had experienced previous intolerance to contact lenses. 
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All patients exhibited good compliance with Xiloial treatment, 
with optimal tolerability and no adverse effects. In this respect, 
no blurring, itching, or scratching after the trial instillation were 
reported by any patient while wearing their contact lenses.
A statistically significant reduction in subjective symp-
toms was observed after one month of treatment, and in 12 
of 15 patients the OSDI value reached the normal symptom 
score at the endpoint. In our opinion, residual subjective 
symptoms could be related to the never stopped contact lens 
wear in itself, although no relationship with the contact lens 
regimen was found.
A statistically significant increase in TFBUT values 
was demonstrated in all patients stepwise with duration of 
treatment, but no subject reached the normal TFBUT value 
of higher than 10 seconds. On the other hand, continued 
wearing of contact lens during treatment could account for 
these results, because a decrease in TFBUT is recognized as 
a major side effect of contact lenses.29
Seven of 15 patients showed a normal tear ferning grade 
at baseline, even in the presence of subjective   symptoms 
of   discomfort, which appears to be in disagreement 
with   previous authors who have shown tear ferning to be a 
good predictor of successful tolerance to contact lens wear.30 
As previously suggested,21 the interpretation of tear ferning 
appears to be related to the ionic content in tears. In this study, 
tear ferning appeared significantly reduced compared with 
normal values after treatment, possibly due to tear dilution 
performed by the substitute.
Both corneal and conjunctival surface epithelial dam-
age were significantly reduced already after one month of 
treatment, and complete epithelial healing was shown in 19 
of 30 eyes at the endpoint. This result is particularly inter-
esting if one considers that epithelial integrity was restored 
after treatment, even in the presence of contact lens wearing 
onsite. This observation supports the mucomimetic action 
of Xiloial, and its ability to perform a protective role as a 
polymer interposing between the corneal epithelium and the 
contact lens.
Patients had been selected ad hoc with normal Schirmer I 
values as an inclusion criterion for this study in order to 
reduce study variables and to enrol patients with mild subjec-
tive discomfort. A small, but statistically significant, increase 
in Schirmer value was noted at endpoint versus baseline. 
However, the reliability of the Schirmer test has been debated 
recently due to the large coefficients of variation in repeated 
measures, unless for values lower than three mm wet strip 
length.31 Therefore, it is feasible that the 2 mm increase in 
Schirmer values observed in our study is related more to test 
variability than to treatment efficacy.
Serum albumin in tears is considered to be an indi-
rect index of inflammation as a consequence of passive 
exudation due to increased leakage from blood vessels.32 
Increased serum albumin levels in contact lens wearers’ 
tears are already reported in the literature and, the higher 
the concentration, the greater the degree of deposition that 
can be expected on the lens, particularly for dry eye.33 Paired 
statistical analysis of all patients did not show any statisti-
cally significant differences in serum albumin content in 
tears. Interestingly, a significant decrease in exudated serum 
albumin was only shown in the subgroup of patients who 
had not previously reported single or repeated episodes of 
intolerance to contact lens wear. A slight, but not significant, 
increase was shown in the subgroup of patients who reported 
previous intolerance to contact lenses. We recognize that no 
conclusions can be drawn from the present study due to the 
limited number of patients, but it can be speculated that the 
conjunctival response may change after intolerance, as has 
been suggested for overnight contact lenses.34
As a concluding remark, a two-month treatment with the 
newly formulated copolymer Xiloial® in symptomatic dSCL 
wearers still wearing the device showed:
•  high tolerability
•  reduction in subjective symptoms
•  reduction in ocular surface epithelial damage
•  increase in TFBUT value
•  reduction of exudated serum albumin in tears in about 
half of patients.
Disclosure
The investigators have no proprietary interest in the tested 
product. No financial arrangements have been made where 
study outcome could affect compensation.
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